In vitro assessment of halobacterial gas vesicles as a Chlamydia vaccine display and delivery system

Vaccine

Volumn 30, Issue 41, 2012, Pages 5942-5948

  Childs, Tawanna S ^a   Webley, Wilmore C ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Adjuvant; Chlamydia; Delivery system; Gas vesicles; Halobacteria; Vaccine

Indexed keywords

BACTERIAL VACCINE; CHLAMYDIA VACCINE; GAS VESICLE PROTEIN C; MAJOR OUTER MEMBRANE PROTEIN; MEMBRANE PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; OUTER MEMBRANE COMPLEX B; POLYMORPHIC OUTER MEMBRANE PROTEIN D; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BACTERIAL GENE; CELL STRUCTURE; DRUG DELIVERY SYSTEM; GAS VESICLE; HALOBACTERIUM SALINARUM; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CELL LINE; CHLAMYDIA TRACHOMATIS; CLONING, MOLECULAR; CYTOPLASMIC VESICLES; DNA, BACTERIAL; HALOBACTERIUM; HUMANS; IMMUNE SERA; INTERLEUKIN-12; INTERLEUKIN-6; MICE; MYELOID DIFFERENTIATION FACTOR 88; PROTEINS; RECOMBINANT PROTEINS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865346920     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.038     Document Type: Article

References (41)

1. World Health Organization DoRHaR Prevalence and Incidence of Selected Sexually Transmitted Infections 2011, World Health Organization, Geneva, Swizerland.
2. Taylor H.R. Doyne lecture: trachoma, is it history?. Eye (Lond) 2009, 23(November (11)):2007-2022.
3. Mariotti S.P., Pascolini D., Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol 2009, 93(May (5)):563-568.
4. Stamm W.E. Chlamydia trachomatis infections: progress and problems. J Infect Dis 1999, 179(March (Suppl. 2)):S380-S383.
5. Land J.A., Van Bergen J.E., Morre S.A., Postma M.J. Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update 2010, 16(March-April (2)):189-204.
6. Igietseme J.U., Eko F.O., Black C.M. Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. Expert Rev Vaccines 2011, 10(November (11)):1585-1596.
7. Schautteet K., De Clercq E., Vanrompay D. Chlamydia trachomatis vaccine research through the years. Infect Dis Obstet Gynecol 2011, 2011.
8. Karunakaran K.P., Yu H., Foster L.J., Brunham R.C. Development of a Chlamydia trachomatis T cell vaccine. Hum Vaccines 2010, 6(August (8)):676-680.
9. Rockey D.D., Wang J., Lei L., Zhong G. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines 2009, 8(October (10)):1365-1377.
10. Woolridge R., Grayston J., Chang I., Yang C., Cheng K. Long-term follow-up of the initial (1959-1960) trachoma vaccine field trial on Taiwan. Am J Ophthalmol 1967, 165(63):0-5.
11. Ortiz L., Angevine M., Kim S.K., Watkins D., DeMars R. T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humans. Infect Immun 2000, 68(March (3)):1719-1723.
12. Stagg A.J., Elsley W.A., Pickett M.A., Ward M.E., Knight S.C. Primary human T-cell responses to the major outer membrane protein of Chlamydia trachomatis. Immunology 1993, 79(May (1)):1-9.
13. Zhu S., Chen J., Zheng M., Gong W., Xue X., Li W., et al. Identification of immunodominant linear B-cell epitopes within the major outer membrane protein of Chlamydia trachomatis. Acta Biochim Biophys Sin 2010, 42(11):8.
14. Caldwell H.D., Kromhout J., Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun 1981, 31(March (3)):1161-1176.
15. Frikha-Gargouri O., Gdoura R., Znazen A., Gargouri B., Gargouri J., Rebai A., et al. Evaluation of an in silico predicted specific and immunogenic antigen from the OmcB protein for the serodiagnosis of Chlamydia trachomatis infections. BMC Microbiol 2008, 8:217.
16. Olsen A.W., Theisen M., Christensen D., Follmann F., Andersen P. Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model. PLoS One 2010, 5(5):e10768.
17. Qi M., Gong S., Lei L., Liu Q., Zhong G. A Chlamydia trachomatis OmcB C-terminal fragment is released into the host cell cytoplasm and is immunogenic in humans. Infect Immun 2011, 79(June (6)):2193-2203.
18. Gomes J.P., Nunes A., Bruno W.J., Borrego M.J., Florindo C., Dean D. Polymorphisms in the nine polymorphic membrane proteins of Chlamydia trachomatis across all serovars: evidence for serovar Da recombination and correlation with tissue tropism. J Bacteriol 2006, 188(January (1)):275-286.
19. Tan C., Hsia R.C., Shou H., Haggerty C.L., Ness R.B., Gaydos C.A., et al. Chlamydia trachomatis-infected patients display variable antibody profiles against the nine-member polymorphic membrane protein family. Infect Immun 2009, 77(August (8)):3218-3226.
20. Stothard D.R., Toth G.A., Batteiger B.E. Polymorphic membrane protein H has evolved in parallel with the three disease-causing groups of Chlamydia trachomatis. Infect Immun 2003, 71(March (3)):1200-1208.
21. Crane D.D., Carlson J.H., Fischer E.R., Bavoil P., Hsia R.C., Tan C., et al. Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc Natl Acad Sci USA 2006, 103(February (6)):1894-1899.
22. Wehrl W., Brinkmann V., Jungblut P.R., Meyer T.F., Szczepek A.J. From the inside out--processing of the Chlamydial autotransporter PmpD and its role in bacterial adhesion and activation of human host cells. Mol Microbiol 2004, 51(January (2)):319-334.
23. Brunham R.C., Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005, 5(February (2)):149-161.
24. Farris C.M., Morrison S.G., Morrison RP CD4+ T cells and antibody are required for optimal MOMP vaccine induced immunity to Chlamydia muridarum genital infection. Infect Immun 2010, (July).
25. Xu W., Liu J., Gong W., Chen J., Zhu S., Zhang L. Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1. Vaccine 2011, 29(March (15)):2672-2678.
26. Offner S., Ziese U., Wanner G., Typke D., Pfeifer F. Structural characteristics of halobacterial gas vesicles. Microbiology 1998, 144(May (5)):1331-1342.
27. Walsby A.E. Gas vesicles. Microbiol Rev 1994, 58(March (1)):94-144.
28. Pfeifer F., Kruger K., Roder R., Mayr A., Ziesche S., Offner S. Gas vesicle formation in halophilic archaea. Arch Microbiol 1997, 167(May (5)):259-268.
29. Halladay J.T., Jones J.G., Lin F., MacDonald A.B., DasSarma S. The rightward gas vesicle operon in Halobacterium plasmid pNRC100: identification of the gvpA and gvpC gene products by use of antibody probes and genetic analysis of the region downstream of gvpC. J Bacteriol 1993, 175(February (3)):684-692.
30. Hayes P.K., Buchholz B., Walsby A.E. Gas vesicles are strengthened by the outer-surface protein, GvpC. Arch Microbiol 1992, 157(3):229-234.
31. Offner S., Wanner G., Pfeifer F. Functional studies of the gvpACNO operon of Halobacterium salinarium reveal that the GvpC protein shapes gas vesicles. J Bacteriol 1996, 178(April (7)):2071-2078.
32. Akolkar A.V., Durai D., Desai AJ Halobacterium sp. SP1(1) as a starter culture for accelerating fish sauce fermentation. J Appl Microbiol 2010, 109(1):10.
33. Sremac M., Stuart E.S. Recombinant gas vesicles from Halobacterium sp. displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle. BMC Biotechnol 2008, 8:9.
34. Scidmore M.A. Cultivation and laboratory maintenance of Chlamydia trachomatis. Curr Protoc Microbiol 2005, (July). Chapter 11:Unit 11A 1.
35. Stuart E.S., Morshed F., Sremac M., DasSarma S. Cassette-based presentation of SIV epitopes with recombinant gas vesicles from halophilic archaea. J Biotechnol 2004, 114(November (3)):225-237.
36. Igietseme J.U., Eko F.O., He Q., Bandea C., Black C.M. Developing effective delivery systems for Chlamydia vaccines. Curr Opin Mol Ther 2004, 6(April (2)):182-194.
37. Sharma J., Zhong Y., Dong F., Piper J.M., Wang G., Zhong G. Profiling of human antibody responses to Chlamydia trachomatis urogenital tract infection using microplates arrayed with 156 chlamydial fusion proteins. Infect Immun 2006, 74(March (3)):1490-1499.
38. Eko F.O., Okenu D.N., Singh U.P., He Q., Black C., Igietseme J.U. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine 2011, 29(May (21)):3802-3810.
39. Pal S., Theodor I., Peterson E.M., de la Maza L.M. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun 2001, 69(October (10)):6240-6247.
40. Ekong E.E., Okenu D.N., Mania-Pramanik J., He Q., Igietseme J.U., Ananaba G.A., et al. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin. FEMS Immunol Med Microbiol 2009, 55(March (2)):280-291.
41. Igietseme J.U., Murdin A. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. Infect Immun 2000, 68(December (12)):6798-6806.